Fate Therapeutics Inc [FATE] stock prices are up 4.10% to $2.79 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The FATE shares have gain 12.05% over the last week, with a monthly amount drifted -9.12%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Fate Therapeutics Inc [NASDAQ: FATE] stock has seen the most recent analyst activity on June 17, 2024, when Piper Sandler upgraded its rating to a Overweight and also boosted its price target to $6 from $4. On January 24, 2023, downgrade downgraded it’s rating to Neutral and revised its price target to $7 on the stock. Wedbush downgraded its rating to a Neutral and decreased its price target to $7 on January 06, 2023. Truist downgraded its rating to a Hold and reduced its price target to $7 on January 06, 2023. Stifel downgraded its rating to Hold for this stock on January 06, 2023, and downed its price target to $5.30. In a note dated January 06, 2023, Piper Sandler downgraded an Neutral rating on this stock and revised its target price from $71 to $12.
The stock price of Fate Therapeutics Inc [FATE] has been fluctuating between $1.91 and $8.83 over the past year. Currently, Wall Street analysts expect the stock to reach $39.75 within the next 12 months. Fate Therapeutics Inc [NASDAQ: FATE] shares were valued at $2.79 at the most recent close of the market. An investor can expect a potential return of 1324.73% based on the average FATE price forecast.
Analyzing the FATE fundamentals
The Fate Therapeutics Inc [NASDAQ:FATE] reported sales of 12.32M for trailing twelve months, representing a surge of 625.83%. Gross Profit Margin for this corporation currently stands at -0.56% with Operating Profit Margin at -15.87%, Pretax Profit Margin comes in at -14.27%, and Net Profit Margin reading is -14.27%. To continue investigating profitability, this company’s Return on Assets is posted at -0.33, Equity is -0.44 and Total Capital is -0.4. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.25.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.67 points at the first support level, and at 2.56 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.90, and for the 2nd resistance point, it is at 3.01.
Ratios To Look Out For
It’s worth pointing out that Fate Therapeutics Inc [NASDAQ:FATE]’s Current Ratio is 9.18. As well, the Quick Ratio is 9.18, while the Cash Ratio is 1.06. Considering the valuation of this stock, the price to sales ratio is 25.79, the price to book ratio is 0.80.
Transactions by insiders
Recent insider trading involved Xu Yuan, Director, that happened on Aug 06 ’24 when 633.0 shares were sold. Director, Xu Yuan completed a deal on Aug 06 ’24 to buy 633.0 shares. Meanwhile, Chief Financial Officer Dulac Edward J III sold 2447.0 shares on Mar 04 ’24.
